A case of disseminated bilateral pulmonary adiaspiromycosis is reportd in a two year old Finnish girl. She recovered from this rare infection after treatment with amphotericin B. She is the first human case of adiaspiromycosis in Scandinavia and she is the youngest child with this disease reported so far. Electron microscopy showed that the three layers of the spore wall were not typical; rather, there seemed to be a gradual transition between the main wall zones, which may be split into an indefinite number of thin layers. Varying numbers and thicknesses were seen with different staining methods, and in different spores. Diagnosis relies on recognition of the fungus in a pulmonary biopsy specimen, because there are no reliable serological tests and culture ofthe fungus is time consuming and not always successful. It was thought that this patient had become infected as a result of contact with soil dust containing the spores in the yard surrounding her home, and as a result of her mother's work in a large garden shop. (7 Clin Pathol 1997;50:82-85) 
Adiaspiromycosis is a pulmonary fungal infection of worldwide distribution which affects lower order mammals and, rarely, humans. The causative agents are two variants of the saprophytic soil mould Emmonsia parva (Chrysosporium parvum). Adiaspiromycosis was first discovered in rodents from Transcaucasia (Russia), ' Both variants produce asexual conidia 2-5 ,um in diameter, which, after being inhaled into the lung, are uniquely able to enlarge progressively beyond the ordinary fungal cell size. The variants differ in such a way that the spores of E var. parva do not essentially exceed a diameter of 40 tIm, whereas the E var. crescens spores may grow up to 400 ,um or more.5 It is believed that the conidia do not replicate in the lung, nor do they migrate or disseminate to any extent.7 Consequently, adiaspiromycosis is essentially restricted to the lungs. The spherules induce a granulomatous reaction, in which a single spherule is surrounded by a fibronecrotic and suppurative or fibrous granuloma. The disease can be localised and symptomless, or disseminated, occasionally severe, or even fatal. 4 The severity and extent of the disease in the lungs depends on the amount of the dustborne conidia inhaled.
We present a case of a two year old girl with disseminated pulmonary adiaspiromycosis, who was successfully treated with amphotericin B. She is, as far as we know, the first girl with this disease.
Case report
The patient, a Caucasian girl, lived in a small town in a new apartment building. The landscaping of the courtyard was under way, with heaps of garden soil around, where the children liked to play. The child's mother was working in a garden shop. The family had no pets. Since the age of one year, the patient had experienced recurrent attacks ofwheeze, and at the age of 1.5 years, her respiratory distress was diagnosed as asthma. The treatment consisted of daily inhalations of sodium cromoglycate using a metered dose inhalator with a spacer and additional oral salbutamol during attacks.
At the age of one year and 10 months, the patient became ill with fever and a dry cough. Her The chest x-ray film showed heavy interst infiltration in both lungs. The patient was charged with a prescription for oral erythro cin.
At follow up two weeks later, she was as ptomatic. The x-ray film was unchanged, she was K4~Microscopically, eight to 25 granulomas were seen in every section (fig 1 A) intermixed with plasma cells, lymphocytes, and polymorphonuclear leucocytes. The outer zone was dominated by proliferating macrophages. In the middle and outer zones, a few histiocytic giant cells and PAS positive phagocytes were found.
Electron microscopy verified the complex structure of the adiaspore wall (fig 2) . The inner and outer layers were more amorphous than the middle layer. The inner layer was of varying thickness, showing cytoplasmic remnants, including membraneous and vesicular components and homogeneous or slightly fibrillar material. The middle layer, [4] [5] [6] [7] The mycelial growth of E parva var. crescens in soil produces conidia 2-5 gm in diameter, which are inhaled by small mammals or, occasionally, by people. In the lungs of mammals, the conidia begin to extend their diameter and wall thickness without a definite upper limit, but, for some reason, they do not divide. The natural life cycle of E parva is poorly known, and the cases of adiaspiromycosis may represent only random, malformations of fungal development. There is some evidence to suggest, however, that the spores could return in a viable state to the soil after the death of the host mammal and give rise to a new generation of mycelial growth and normal sized aleuriospores.'°The incidence and evolutionary importance of this alternative cycle for the fungus remain speculative.
The patient reported here had asthma, which was treated with daily inhalations of sodium cromoglycate, using a metered dose inhalator with a spacer, and additional oral salbutamol during mild attacks. Corticosteroids were not used. Some of the patients reported before have been healthy, while others have had diverse pulmonary disorders, including emphysema, tuberculosis, aspergillosis, and pulmonary abscesses, and two patients have been immunocompromised.4 However, among those who have had adiaspiromycosis, no common cause which would have made them susceptible to the infection has been detected. The reason why some people become infected while most do not remains a mystery. Many of the patients reported so far were engaged in outdoor activities and were therefore at risk of exposure to dust. In line with this, our patient had been exposed to soil dust containing spores because of the landscaping of the courtyard. The mother's work in a large garden shop could also be considered a potential source for variable soil inocula. For all that, considering the worldwide occurrence of E parva var. crescens, the cases of manifest disease or even incidental necropsy findings are astonishingly rare.
The patient was treated for two weeks with intravenous amphotericin B 0.5 mg/kg/day. There have been reports of the use of monotherapy or combinations of amphotericin B, 5-fluorocytosine, ketoconazole, itraconazole, and systemic corticosteroids in pulmonary adiospiromycosis. A patient with osteomyelitis caused by Chrysosporium has also been treated succesfully with amphotericin B." However, few patients with disseminated adiaspiromycosis of the lung have recovered without treatment.4 Because disseminated adiaspiromycosis has been reported to be fatal4 and our patient showed heavy diffuse interstitial infiltration in both lungs, she was treated with amphotericin B. A slight decrease in the pulmonary infiltration was seen at the end of treatment, and after one year the chest x-ray film was normal. We consider antifungal treatment logical in such cases, because adiaspores are living organisms which provoke an interstitial granulomatous reaction, with compression of the adjacent blood vessels and bronchioli, thus potentially compromising pulmonary function.
According to our observations, the 'three layers' of the spore wall4 should not be considered a consistent feature. For the time being, we would like to use the term 'multilaminar'.
We emphasise the gradual transition between all the main wall zones, which may progressively and irregularly split into an indefinite number of thin layers. Of 
